الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 240 |  |  |
| | | from | 240 | | |
Abstract
Breast cancer is the most common type of diagnosed cancers in
women accounting for 24.2% of the total new cancer cases in 2018
and accounting for 15.0% of cancer related deaths among women
worldwide ranking as the first leading cause of cancer related deaths
among them.
In Egypt, Breast cancer represents 38.8% of cancers occurring
in Egyptian females in 2014 and it increases lineary as population
increase. Additionally, it accounts 15.4% in both sexes. Breast cancers
have been classified according to the histopathological type, grade and
stage.
During the last decade, five molecular subtypes of breast
carcinoma (BC) (luminal A, luminal B, HER2/neu-positive, basallike,
and normal breast-like) have been characterized and intensively
studied based on molecular classification. Classifications may help in
prognostication and targeting of treatment to those most likely to
benefit.
However, current classification systems are descriptive, based
on morphological entities and immunohistochemistry (IHC) findings
that have been shown to have prognostic implications. For the success
of targeted therapies and individualized medicine, a predictive rather
than purely prognostic classification system is required.
Mortalin (HSPA9/GRP75/PBP74), a member of the heat shock
protein (HSP) 70 family is often overexpressed in different tumor
types, including breast, colon, liver, brain, thyroid and skin cancers.
Although Mortalin was originally identified as a mitochondrial
molecular chaperone, it is often detected in different subcellular